Revelation Biosciences Stock Probability Of Bankruptcy

REVB Stock  USD 4.18  0.13  3.02%   
Revelation Biosciences' chance of distress is above 80% at the present time. It has very high odds of going through financial hardship in the upcoming years. Chance of distress shows the probability of financial torment over the next two years of operations under current economic and market conditions. All items used in analyzing the odds of distress are taken from the Revelation balance sheet, as well as cash flow and income statements available from the company's most recent filings. Check out Revelation Biosciences Piotroski F Score and Revelation Biosciences Altman Z Score analysis.
For information on how to trade Revelation Stock refer to our How to Trade Revelation Stock guide.
  

Revelation Biosciences Company chance of distress Analysis

Revelation Biosciences' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.

Probability Of Bankruptcy

 = 

Normalized

Z-Score

More About Probability Of Bankruptcy | All Equity Analysis

Current Revelation Biosciences Probability Of Bankruptcy

    
  Over 85%  
Most of Revelation Biosciences' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Revelation Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Revelation Biosciences probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Revelation Biosciences odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Revelation Biosciences financial health.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Revelation Biosciences. If investors know Revelation will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Revelation Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Revelation Biosciences is measured differently than its book value, which is the value of Revelation that is recorded on the company's balance sheet. Investors also form their own opinion of Revelation Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Revelation Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Revelation Biosciences' market value can be influenced by many factors that don't directly affect Revelation Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Revelation Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Revelation Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Revelation Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
Competition

Based on the latest financial disclosure, Revelation Biosciences has a Probability Of Bankruptcy of 85%. This is 96.35% higher than that of the Biotechnology sector and 55.0% higher than that of the Health Care industry. The probability of bankruptcy for all United States stocks is 113.41% lower than that of the firm.

Revelation Probability Of Bankruptcy Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Revelation Biosciences' direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Revelation Biosciences could also be used in its relative valuation, which is a method of valuing Revelation Biosciences by comparing valuation metrics of similar companies.
Revelation Biosciences is currently under evaluation in probability of bankruptcy category among its peers.

Revelation Fundamentals

About Revelation Biosciences Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Revelation Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Revelation Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Revelation Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Revelation Biosciences is a strong investment it is important to analyze Revelation Biosciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Revelation Biosciences' future performance. For an informed investment choice regarding Revelation Stock, refer to the following important reports:
Check out Revelation Biosciences Piotroski F Score and Revelation Biosciences Altman Z Score analysis.
For information on how to trade Revelation Stock refer to our How to Trade Revelation Stock guide.
You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Revelation Biosciences. If investors know Revelation will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Revelation Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Revelation Biosciences is measured differently than its book value, which is the value of Revelation that is recorded on the company's balance sheet. Investors also form their own opinion of Revelation Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Revelation Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Revelation Biosciences' market value can be influenced by many factors that don't directly affect Revelation Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Revelation Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Revelation Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Revelation Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.